STOCK TITAN

Aktis Oncology (AKTS) director sells 4,856 shares after exercising options

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026. He exercised options for 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share, acquiring 4,856 common shares. He then sold 4,856 common shares at a weighted average price of $24.5622 per share in transactions priced between $24.50 and $24.66.

Positive

  • None.

Negative

  • None.
Insider Herrmann Ken
Role Director
Sold 4,856 shs ($119K)
Approx. gross sale proceeds $119K
Approx. exercise cost $3K
Approx. pre-tax spread $116K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F2 3,506 $0.00 $0.00
Exercise Stock Option (Right to Buy) F2 1,350 $0.00 $0.00
Exercise Common Stock 3,506 $0.08 $280.48
Exercise Common Stock 1,350 $1.91 $3K
Sale Common Stock F1 3,506 $24.5622 $86K
Sale Common Stock F1 1,350 $24.5622 $33K
Holdings After Transaction: Stock Option (Right to Buy) — 18,364 shares (Direct); Common Stock — 0 shares (Direct)
Footnotes (2)
  1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. These options have vested in full.
Shares sold 4,856 shares Common stock sold by director on July 20, 2026
Weighted average sale price $24.5622 per share Sales of common stock at prices from $24.50 to $24.66
Options exercised at $0.08 3,506 shares Stock options exercised at $0.08 per share into common stock
Options exercised at $1.91 1,350 shares Stock options exercised at $1.91 per share into common stock
Total shares from option exercises 4,856 shares Common shares acquired via option exercises before sale
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What transactions did Ken Herrmann report for Aktis Oncology (AKTS)?

Ken Herrmann exercised stock options for 4,856 shares of Aktis Oncology common stock and then sold all 4,856 shares on July 20, 2026, in market transactions at a weighted average sale price of $24.5622 per share.

How many Aktis Oncology (AKTS) shares did Herrmann sell and at what price?

He sold 4,856 shares of Aktis Oncology common stock at a weighted average price of $24.5622 per share, with individual trade prices ranging from $24.50 to $24.66 during the reported transactions on July 20, 2026.

What stock options did Herrmann exercise in this AKTS insider transaction?

Herrmann exercised options covering 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share. These vested stock options converted into 4,856 shares of common stock, which were then sold the same day at market prices.

Were the Aktis Oncology (AKTS) stock options fully vested when exercised?

Yes. A footnote states that these options had vested in full at the time of exercise. That means the options were fully earned and exercisable when Herrmann converted them into common shares before selling those shares.

Was Herrmann’s AKTS trade under a Rule 10b5-1 trading plan?

No. These transactions are not designated as taking place under a Rule 10b5-1 trading plan, indicating they are reported as discretionary insider trades rather than trades executed pursuant to a pre-arranged trading plan.

Did Ken Herrmann retain any Aktis Oncology (AKTS) shares from these option exercises?

From this sequence, he acquired 4,856 shares via option exercise and then sold 4,856 shares of common stock. Based on the reported amounts, these particular exercises and sales did not increase his common share holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Herrmann Ken

(Last)(First)(Middle)
C/O AKTIS ONCOLOGY, INC.
17 DRYDOCK AVENUE, SUITE 17-401

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/20/2026M3,506A$0.083,506D
Common Stock07/20/2026M1,350A$1.914,856D
Common Stock07/20/2026S3,506D$24.5622(1)1,350D
Common Stock07/20/2026S1,350D$24.5622(1)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.0807/20/2026M3,506 (2)11/23/2030Common Stock3,506$00D
Stock Option (Right to Buy)$1.9107/20/2026M1,350 (2)04/14/2031Common Stock1,350$018,364D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. These options have vested in full.
/s/ Kyle D. Kuvalanka, as Attorney-in-Fact07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)